Back to results
US 9,175,086 B2Granted
CD20 antibodies and uses thereof
AssigneeImmunoGen, Inc.
InventorsJutta Deckert, Daniel J. Tavares, Peter U. Park
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeImmunoGen, Inc.
InventorsJutta Deckert, Daniel J. Tavares, Peter U. Park
Estimating the term…
CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 23-25, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 26-28, respectively.
An isolated antibody or antigen-binding fragment thereof that specifically binds to CD20, wherein said antibody or fragment comprises a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs:
An antibody produced by the hybridoma (ATCC Accession No. PTA-10485) or an antigen-binding fragment thereof.
Dependencies are inferred from the claim text.